{"entity":{"id":"lvgn6051","kind":"drug","name":"LVGN6051","aka":[],"tldr":"LVGN6051 is a monoclonal antibody from Lyvgen Biopharma Holdings Limited, in registered phase 2 trials for head and neck squamous cell carcinoma.","summary":"LVGN6051 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Lyvgen Biopharma Holdings Limited, in head and neck squamous cell carcinoma. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of LVGN6051","url":"https://clinicaltrials.gov/search?intr=LVGN6051"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06378177"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"LVGN6051","modality":"Monoclonal antibody","mechanism":"A monoclonal antibody, as described in the registry record.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lvgn6051/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"trial":[{"id":"nct06378177","kind":"trial","name":"A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)","route":"/trials/nct06378177/"}]}}